Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (NY:HLN)

10.51 -0.05 (-0.47%)
Streaming Delayed Price Updated: 1:07 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 Next >
News headline image
Kimberly-Clark's Mega-Bid for Kenvue: A $48.7 Billion Consumer Staples Shakeup
In a move that signals a seismic shift within the consumer staples landscape, Kimberly-Clark (NYSE:KMB) is on the precipice of finalizing its $48.7 billion acquisition of Kenvue (NYSE:KVUE). This... 
Via MarketMinute
Topics Economy
News headline image
The New Titan of Wellness: Kimberly-Clark’s $48.7 Billion Kenvue Acquisition Reshapes Consumer Staples
In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health... 
Via MarketMinute
Topics Initial Public Offering Supply Chain
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Top 2 Risk Off Stocks That May Implode In August ↗
 
Via Benzinga
News headline image
Current Analysis: Haleon ↗
Haleon (HLN​​​​​​​) is one of the largest consumer health companies in the world. Over the past year, Haleon PLC share price rose 13.8% from $7.60 to $8.66 as of Tuesday’s market close. 
Via Talk Markets
News headline image
Kenvue Insider Buying and the Kimberly-Clark Megamerger: A Value Investor's Deep Dive
As 2025 draws to a close, the consumer staples sector is witnessing one of its most dramatic transformations in decades. The recent announcement that Kimberly-Clark (NYSE:KMB) will acquire Kenvue... 
Via MarketMinute
Topics Lawsuit
News headline image
Kenvue's Megadeal Fuels Stock Market Rise at Week's Start: A New Consumer Health Giant Emerges
The financial markets have kicked off the week with a significant surge, largely propelled by the blockbuster acquisition of Kenvue Inc. (NYSE: KVUE) by Kimberly-Clark Corporation (NYSE: KMB). This... 
Via MarketMinute
Topics Supply Chain
News headline image
Salesforce Strengthens AI Offerings Via Vonage, Haleon Tie-Ups ↗
Salesforce (NYSE: CRM) partners with Vonage and Haleon to expand AI, Cloud, and 5G innovation using Data Cloud and Agentforce solutions. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 ↗
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma... 
Via Benzinga
News headline image
NEXGEL Inc. Equity Warrants: A High-Stakes Bet on Future Profitability Amidst Rapid Growth
Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW).... 
Via MarketMinute
Topics Intellectual Property
News headline image
Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence... 
Via MarketMinute
Topics Government Product Recall
News headline image
This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch ↗
 
Via Benzinga
News headline image
KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover ↗
KKR is closing in on a $2.9B takeover of Karo Healthcare after outbidding rivals, reinforcing its aggressive push into European healthcare. 
Via Benzinga
News headline image
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion ↗
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%. 
Via Benzinga
News headline image
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 ↗
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half. 
Via Benzinga
News headline image
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business ↗
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion. 
Via Benzinga
News headline image
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
News headline image
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday? ↗
Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth. 
Via Benzinga
News headline image
What's Going On With Kenvue Stock Monday? ↗
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
Via Benzinga
News headline image
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies ↗
Elf Beauty appeared to rally along with KVUE on Monday. 
Via Investor's Business Daily
Topics Stocks
News headline image
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
News headline image
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon ↗
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company. 
Via Benzinga
News headline image
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
News headline image
Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
News headline image
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M ↗
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... 
Via Benzinga
News headline image
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
News headline image
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale ↗
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
News headline image
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B ↗
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
News headline image
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars ↗
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.